These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 32072673)

  • 21. Impact of clinicopathologic features on leptomeningeal metastasis from lung adenocarcinoma and treatment efficacy with epidermal growth factor receptor tyrosine kinase inhibitor.
    Kwon BS; Cho YH; Yoon SK; Lee DH; Kim SW; Kwon DH; Lee JC; Choi CM
    Thorac Cancer; 2020 Feb; 11(2):436-442. PubMed ID: 31910497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tyrosine kinase inhibitors may change the metastatic pattern.
    Sendur MA; Aksoy S; Ozdemir NY; Zengin N
    J BUON; 2013; 18(2):544. PubMed ID: 23818376
    [No Abstract]   [Full Text] [Related]  

  • 23. There is still a role for cytology in the 'liquid biopsy' era. A lesson from a TKI-treated patient showing adenocarcinoma to squamous cell carcinoma transition during disease progression.
    Clery E; Pisapia P; Feliciano S; Vigliar E; Marano A; De Luca C; Malapelle U; Troncone G; Bellevicine C
    J Clin Pathol; 2017 Sep; 70(9):798-802. PubMed ID: 28363898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and EGFR-Mutated Lung Adenocarcinoma.
    Tambo Y; Sone T; Kasahara K
    J Thorac Oncol; 2017 Dec; 12(12):e199-e200. PubMed ID: 29169523
    [No Abstract]   [Full Text] [Related]  

  • 25. Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project.
    Beau-Faller M; Pencreach E; Leduc C; Blons H; Merlio JP; Bringuier PP; de Fraipont F; Escande F; Lemoine A; Ouafik L; Denis M; Hofman P; Lacave R; Melaabi S; Langlais A; Missy P; Morin F; Moro-Sibilot D; Barlesi F; Cadranel J;
    Lung Cancer; 2020 Feb; 140():19-26. PubMed ID: 31841714
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma.
    Kang DH; Jung SS; Yeo MK; Lee DH; Yoo G; Cho SY; Oh IJ; Kim JO; Park HS; Chung C; Lee JE
    BMC Cancer; 2020 Jun; 20(1):571. PubMed ID: 32552717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
    Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH
    BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early serum tumor marker levels after fourteen days of tyrosine kinase inhibitor targeted therapy predicts outcomes in patients with advanced lung adenocarcinoma.
    Chen HJ; Tu CY; Huang KY; Chien CR; Hsia TC
    PLoS One; 2020; 15(12):e0240736. PubMed ID: 33306683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative effectiveness of concurrent chemoradiotherapy versus EGFR-tyrosine kinase inhibitors for the treatment of clinical stage IIIb lung adenocarcinoma patients with mutant EGFR.
    Hsia TC; Liang JA; Li CC; Chien CR
    Thorac Cancer; 2018 Nov; 9(11):1398-1405. PubMed ID: 30152040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical significance of serum EGFR gene mutation and serum tumor markers in predicting tyrosine kinase inhibitor efficacy in lung adenocarcinoma.
    Feng LX; Wang J; Yu Z; Song SA; Zhai WX; Dong SH; Yu HS; Zhang Y
    Clin Transl Oncol; 2019 Aug; 21(8):1005-1013. PubMed ID: 30637712
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and Efficacy of Alectinib in a Patient With Advanced NSCLC Undergoing Hemodialysis.
    Suzuki S; Haratani K; Takahama T; Watanabe S; Takegawa N; Hayashi H; Takeda M; Yonesaka K; Nakagawa K
    J Thorac Oncol; 2019 Mar; 14(3):e50-e52. PubMed ID: 30782383
    [No Abstract]   [Full Text] [Related]  

  • 32. Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population.
    Zeng L; Xiao L; Jiang W; Yang H; Hu D; Xia C; Li Y; Zhou C; Xiong Y; Liu L; Liao D; Guan R; Li K; Wang J; Zhang Y; Yang N; Mansfield AS
    Lung Cancer; 2020 Mar; 141():82-88. PubMed ID: 31982639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary Resistance to Alectinib Was Lost after Bevacizumab Combined Chemotherapy in ALK-Rearranged Lung Adenocarcinoma.
    Nakasuka T; Ichihara E; Makimoto G; Maeda Y; Kiura K
    J Thorac Oncol; 2019 Aug; 14(8):e168-e169. PubMed ID: 31345339
    [No Abstract]   [Full Text] [Related]  

  • 34. Complex epidermal growth factor receptor mutations and their responses to tyrosine kinase inhibitors in previously untreated advanced lung adenocarcinomas.
    Zhang B; Wang S; Qian J; Yang W; Qian F; Lu J; Zhang Y; Qiao R; Han B
    Cancer; 2018 Jun; 124(11):2399-2406. PubMed ID: 29543321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer.
    Besse B; Garrido P; Cortot AB; Johnson M; Murakami H; Gazzah A; Gil M; Bennouna J
    Lung Cancer; 2020 Apr; 142():63-69. PubMed ID: 32114283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Efficacy of first generation EGFR-TKIs and chemotherapy as first-line therapy in advanced lung adenocarcinoma patients with uncommon EGFR mutations].
    Li HX; Wang ZZ; Zhang GW; Zhang MN; Zheng XX; Yang JP; Ma ZY; Wang HJ
    Zhonghua Zhong Liu Za Zhi; 2019 Oct; 41(10):783-791. PubMed ID: 31648503
    [No Abstract]   [Full Text] [Related]  

  • 37. Lung adenocarcinoma with sarcomatoid transformation after tyrosine kinase inhibitor treatment and chemotherapy.
    Hsieh MS; Lin MW; Lee YH
    Lung Cancer; 2019 Nov; 137():76-84. PubMed ID: 31561203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of delaying initiation of anaplastic lymphoma kinase inhibitor treatment on survival in patients with advanced non-small-cell lung cancer.
    Sheinson D; Wong WB; Wu N; Mansfield AS
    Lung Cancer; 2020 May; 143():86-92. PubMed ID: 32276206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The KIF5B-RET Fusion Gene Mutation as a Novel Mechanism of Acquired EGFR Tyrosine Kinase Inhibitor Resistance in Lung Adenocarcinoma.
    Zhu YC; Wang WX; Zhang QX; Xu CW; Zhuang W; Du KQ; Chen G; Lv TF; Song Y
    Clin Lung Cancer; 2019 Jan; 20(1):e73-e76. PubMed ID: 30366769
    [No Abstract]   [Full Text] [Related]  

  • 40. A case of EGFR mutation-positive lung adenocarcinoma in which the T790M allele fraction was increased by repeated EGFR-TKI treatment.
    Kimura H; Amino Y; Koba H; Tambo Y; Ohkura N; Hara J; Sone T; Kasahara K
    Cancer Commun (Lond); 2019 Nov; 39(1):67. PubMed ID: 31675980
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.